Hubei Biocause Pharmaceutical Co (SZSE:000627) Ending Cash Position : ¥21,187 Mil (As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Hubei Biocause Pharmaceutical Co Ending Cash Position?

Hubei Biocause Pharmaceutical Co's Ending Cash Position for the quarter that ended in Mar. 2024 was ¥21,187 Mil.

Hubei Biocause Pharmaceutical Co's quarterly Ending Cash Position increased from Sep. 2023 (¥25,635 Mil) to Dec. 2023 (¥28,145 Mil) but then declined from Dec. 2023 (¥28,145 Mil) to Mar. 2024 (¥21,187 Mil).

Hubei Biocause Pharmaceutical Co's annual Ending Cash Position increased from Dec. 2021 (¥23,250 Mil) to Dec. 2022 (¥26,309 Mil) and increased from Dec. 2022 (¥26,309 Mil) to Dec. 2023 (¥28,145 Mil).

Hubei Biocause Pharmaceutical Co Ending Cash Position Historical Data

The historical data trend for Hubei Biocause Pharmaceutical Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hubei Biocause Pharmaceutical Co Ending Cash Position Chart

Hubei Biocause Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

12,979.55

26,857.15

23,250.30

26,309.32

28,145.38

Hubei Biocause Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial															31,777.13	38,148.97	25,634.60	28,145.38	21,186.58

Hubei Biocause Pharmaceutical Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Hubei Biocause Pharmaceutical Co's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	26309.324	+	1836.053
	=	28,145

Hubei Biocause Pharmaceutical Co's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	28145.376	+	-6958.796
	=	21,187

Hubei Biocause Pharmaceutical Co Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Hubei Biocause Pharmaceutical Co's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Hubei Biocause Pharmaceutical Co (SZSE:000627) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Insurance » Hubei Biocause Pharmaceutical Co Ltd (SZSE:000627) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

2nd Floor, Building 1, No. 1 Tianshan Road, Guohua Huijin Center, Zhanghe New District, Hubei Province, Jingmen, CHN, 448000

Website

http://www.tianmaogroup.net

Hubei Biocause Pharmaceutical Co Ltd is a China-based company engaged in life insurance, health insurance, accident insurance, and other life insurance businesses, medicine, and chemical businesses. The company generates its revenue in the form of premiums.

Executives

Jiang Hai Hua	Independent director
Fu Yong Jin	Directors, executives
Wu Shi Yan	Supervisors

Hubei Biocause Pharmaceutical Co (SZSE:000627) Headlines

No Headlines